Potluri Sandeep, Lawson Sarah, Kishore Shyla, Ogboli Malobi, Hartley Jane, Alfred Arun, Wilson Yvonne, Mirza Darius F, Sharif Khalid, Gupte Girish
Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom.
Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom.
Transplant Direct. 2025 Jun 27;11(7):e1830. doi: 10.1097/TXD.0000000000001830. eCollection 2025 Jul.
Graft-versus-host-disease (GvHD) is an infrequent but serious complication of small intestinal transplantation in children, which is associated with a very poor prognosis. This study evaluated a novel strategy of managing GvHD in these patients through a reduction in immunosuppression.
We conducted a retrospective review 108 consecutive pediatric patients at our center between 2005 and 2021, who had small intestinal transplantation. We assessed clinical features and outcomes as well as laboratory chimerism studies in cohorts of patients before and following a change in treatment strategy for GvHD from intensification to reduction in immunosuppression.
Fourteen percent of pediatric patients developed GvHD after small intestinal transplantation. A change in treatment strategy to a reduction in immunosuppression led to significantly improved overall survival (log rank = 0.015). This improved survival correlated biologically with altered T-cell chimerism dynamics in blood; in patients who had a reduction in immunosuppression, there was abrogation of the rise in donor T-cell chimerism over time seen in the blood of patients who instead had intensification of their immunosuppression. This may be because of permitting recipient lymphocytes to have a host-versus-graft effect and outcompete donor-derived lymphocytes.
Our results demonstrate that that altering the immunosuppressive therapy strategy, following clinical manifestations of GvHD such as a typical skin rash, from intensification to a reduction in immunosuppression led to significantly improved survival.
移植物抗宿主病(GvHD)是儿童小肠移植中一种罕见但严重的并发症,其预后很差。本研究评估了一种通过减少免疫抑制来管理这些患者GvHD的新策略。
我们对2005年至2021年期间在我们中心连续接受小肠移植的108例儿科患者进行了回顾性研究。我们评估了在GvHD治疗策略从强化免疫抑制改为减少免疫抑制之前和之后患者队列的临床特征、结局以及实验室嵌合体研究。
14%的儿科患者在小肠移植后发生了GvHD。将治疗策略改为减少免疫抑制可显著提高总生存率(对数秩检验=0.015)。这种生存率的提高在生物学上与血液中T细胞嵌合动态的改变相关;在免疫抑制减少的患者中,随着时间推移,供体T细胞嵌合体的升高被消除,而在免疫抑制强化的患者血液中则可见这种升高。这可能是因为允许受体淋巴细胞产生宿主抗移植物效应并胜过供体来源的淋巴细胞。
我们的结果表明,在出现典型皮疹等GvHD临床表现后,将免疫抑制治疗策略从强化改为减少免疫抑制可显著提高生存率。